News & Videos - EISAI CO LTD. ESALF

TOKYO, Nov 26, 2019 - (JCN Newswire) - Eisai Co., Ltd. has announced that the latest data on its antiepileptic drug (AED) perampanel (product name: Fycompa) will be presented at the 73rd American Epilepsy Society Annual Meeting (AES 2019) to be held from December 6 to December 10, 2019 in Baltimore, Maryland in the United States. Thirty-Eight poster presentations will be given by Eisai at AES 2019, including results of a Phase III clinical study (FREEDOM / Study 342) to assess efficacy and...

Parkinson's Disease Treatment TOKYO, Nov 20, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has launched the Equfina 50mg TABLETS (safinamide mesilate, "Equfina") for the indication of improvement of the wearing-off phenomenon in patients with Parkinson's disease under treatment with a drug containing levodopa in Japan. Manufacturing and marketing approval of Equfina were obtained on September 20, 2019, and Equfina was included in Japan's National Health Insurance Drug Price...

TOKYO, Nov 5, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into an agreement to transfer the rights to receive royalties on the sales outside of Japan for an investigational anti-cancer agent tazemetostat (generic name) to Royalty Pharma. Tazemetostat is a first-in-class, oral EZH2 inhibitor discovered by Epizyme, Inc. Under the terms of the March 2015 amended and restated agreement with Epizyme, Eisai is responsible for development and commercialization of...

TOKYO, Oct 15, 2019 - (JCN Newswire) - Eisai Co., Ltd. has announced that Eisai received a New Drug Approval for its in-house discovered and developed antiepileptic drug (AED) Fycompa (perampanel) from the China National Medical Products Administration (NMPA) for use in an adjunctive treatment of partial onset seizures (with or without secondarily generalized seizures) in epilepsy patients 12 years of age and older. Fycompa was designated for Priority Review by the NMPA due to its significant...

TOKYO, Oct 1, 2019 - (JCN Newswire) - Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (NYSE: MRK), known as MSD outside the United States and Canada, announced final results from the full endometrial cancer cohort of KEYNOTE- 146/Study 111 evaluating LENVIMA, an orally available kinase inhibitor discovered by Eisai , plus KEYTRUDA, Merck & Co., Inc., Kenilworth, N.J., U.S.A.'s anti-PD-1 therapy. The findings were presented in a proffered paper presentation at the European Society for...

TOKYO, Sept 30, 2019 - (JCN Newswire) - Eisai Co., Ltd. and Nichi-Iko Pharmaceutical have entered into a comprehensive collaboration agreement for the generic pharmaceutical business in China. The Chinese pharmaceutical market is the second largest market in the world after the United States, and the generic drugs account for more than 70% of its market in terms of value. Also, due to the rapid aging and the government's policies to promote the generic drug market, the continuous growth of...

TOKYO, Sept 24, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that a series of abstracts will be presented during the European Society for Medical Oncology (ESMO) 2019 Congress taking place in Barcelona, Spain, from September 27 to October 1, 2019. The abstracts highlight updates regarding Eisai's in-house discovered LENVIMA (lenvatinib mesylate, the orally available kinase inhibitor, "lenvatinib"), and Halaven (eribulin mesylate, "eribulin", halichondrin class microtubule dynamics...

TOKYO, Sept 19, 2019 - (JCN Newswire) - Eisai Co., Ltd. has announced that latest data on lemborexant, an investigational sleep-wake regulation agent being studied for the treatment of sleep-wake disorders, including insomnia and Irregular Sleep-Wake Rhythm Disorder (ISWRD) associated with Alzheimer's disease/dementia will be presented at World Sleep Congress (World Sleep 2019), from September 20 to 25 in Vancouver, Canada. At this congress, oral presentations will be given including the first...

TOKYO, Sept 18, 2019 - (JCN Newswire) - Eisai Co., Ltd. has been selected for a membership in the Dow Jones Sustainability Asia Pacific Index (DJSI Asia Pacific), the Asia Pacific version of the Dow Jones Sustainability Indices (DJSI), which are a family of premier global indices for socially responsible investment (SRI). This marks Eisai's sixth selection. The DJSI family was jointly established between RobecoSAM AG (Switzerland) and S&P Dow Jones Indices LLC (United States) in 1999 and...

TOKYO, Sept 17, 2019 - (JCN Newswire) - Eisai Co., Ltd. has announced that it received the 33rd "IIA Japan Chairman's Award" of the Institute of Internal Auditors - Japan. The IIA Japan was established in 1957 with the aim of contributing to the sound development of Japan's industry and economy through the internal audits. It also functions as Japan's representative organization of The Institution of Internal Auditors (IIA), which plays a role of global leadership in international audits. "IIA...

Eisai And Biogen To Discontinue Phase III Clinical Studies Of BACE Inhibitor Elenbecestat In Early Alzheimer's Disease Discontinuation of studies based on Data Safety Monitoring Board recommendation PR Newswire WOODCLIFF LAKE, N.J., Sept. 13, 2019 WOODCLIFF LAKE, N.J. , Sept. 13, 2019 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo , CEO: Haruo Naito , "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts , CEO: Michel Vounatsos , "Biogen") today announced...

Discontinuation of studies based on Data Safety Monitoring Board recommendation TOKYO, Sept 13, 2019 - (JCN Newswire) - Eisai Co., Ltd and Biogen Inc. today announced the decision to discontinue the Phase III clinical studies (MISSION AD1, AD2) on the investigational oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: E2609) in patients with early Alzheimer's disease (AD). The decision is based on the results of a safety review conducted by the Data Safety...

Alcohol-Free Wipe for Eliminating Viruses and Bacteria on Personal Belongings TOKYO, Aug 29, 2019 - (JCN Newswire) - Eisai Co., Ltd. will launch ETAK( Antimicrobial Wet Wipes (classified as miscellaneous goods) containing long-acting antimicrobial agent ETAK on August 29, 2019 at pharmacies and drugstores countrywide. ETAK, the main ingredient used in the product, is a long-acting antimicrobial agent developed by Professor Hiroki Nikawa of the Department of Oral Biology and Engineering at...

TOKYO, Aug 28, 2019 - (JCN Newswire) - Eisai Co., Ltd. has entered into a business alliance agreement for exclusive development and commercialization of a cognitive function test - Cogstate Brief Battery (CBB) - developed by Cogstate Ltd., in Japan as a digital tool for self-assessment of cognitive function (classified as miscellaneous goods). The CBB consists of four tests, each measuring different cognitive domains: psychomotor function, attention, working memory, and learning, and it has been...

TOKYO, Aug 27, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced that it provides tanks to supply clean water for the neglected tropical diseases (NTDs) measuresto the endemic regions in Kenya in collaboration with Merck. As part of its efforts to improve access to medicines, Eisai manufactures diethylcarbamazine (DEC) tablets, a treatment for a NTD named lymphatic filariasis (LF),at its Visag Plant in India and provides these DEC tablets free of charge to endemic countries through the World...

TOKYO, Aug 1, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that it refresh its SAHNE CREAM (quasi-drug) which has been widely used as medical skin care, for the first time in 20 years, and launch at pharmacies and drug stores in Japan on today August 1, 2019. SAHNE brand marks its 65th anniversary this year. Since the initial launch, SAHNE CREAM has been close to the lifestyle of women who have changed with the times. Eisai is aiming for a brand used by generations around 30's, and...

For LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination Treatment as Potential First-Line Treatment of Patients with Advanced Unresectable Hepatocellular Carcinoma Not Amenable to Locoregional Treatment TOKYO, July 23, 2019 - (JCN Newswire) - Eisai, and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for LENVIMA, the...

TOKYO, July 19, 2019 - (JCN Newswire) - Eisai Co.,Ltd. announced the presentation and discussion about the treatment, including oral beta amyloid cleaving enzyme (BACE) inhibitor elenbecestat(1) research data on Alzheimer's disease(AD), were given in the AAIC's Focused Topic Session "Discussion of BACEi Trial Findings: Challenges and Opportunities" at the Alzheimer's Association International Conference (AAIC) held in Los Angeles, California, United States, from July 14 to 18, 2019.In addition,...

In Cerebrospinal Fluid and the Identification of a Target Engagement Biomarker for the New Anti-Tau Antibody E2814 at Alzheimer's Association International Conference (AAIC) 2019 TOKYO, July 19, 2019 - (JCN Newswire) - Eisai Co.,Ltd. announced that data relating to a new anti-tau antibody E2814(1) was presented at the Alzheimer's Association International Conference (AAIC) held in Los Angeles, California, United States, from July 14 to 18, 2019 (Poster Presentation No.: P4-696). Neurofibrillary...

TOKYO, July 18, 2019 - (JCN Newswire) - Eisai Co.,Ltd. announced its latest research on evaluation about correlation of amyloid beta (Abeta) in plasma and in cerebrospinal fluid (CSF) by high precision measurement with the newly developed automated protein assay system, jointly developed with Sysmex Corporation, using fullautomated immunoassay system HISCLTM(1) series for creating the simplified diagnosis of Alzheimer's disease (AD) with blood was presented at the Alzheimer's Association...